Read by QxMD icon Read

Multiple Sclerosis

shared collection
648 papers 25 to 100 followers
By Alexandros Tsichlakis Medical representative
Ramón Morillo Verdugo, Esther Ramírez Herráiz, Raquel Fernández-Del Olmo, Montserrat Roig Bonet, María Valdivia García
Purpose: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain. Methods: A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments...
2019: Patient Preference and Adherence
Brandi L Vollmer, Kavita V Nair, Stefan Sillau, John R Corboy, Timothy Vollmer, Enrique Alvarez
Objective: To compare 2-year effectiveness and discontinuation of natalizumab (NTZ) versus fingolimod (FTY) and dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). Methods: Patients prescribed NTZ, FTY, or DMF at the Rocky Mountain MS Center at University of Colorado were identified. Clinician-reported data were retrospectively collected. Outcomes include a composite effectiveness measure consisting of new T2 lesion, gadolinium-enhancing lesion, and/or clinical relapse, individual effectiveness outcomes and discontinuation over 2 years...
February 2019: Annals of Clinical and Translational Neurology
Senay Agirgol, Murat Kurtuncu, Mihriban Gurbuzel, Ilay Tasyurek, Tuncay Aygun
No abstract text is available yet for this article.
February 26, 2019: Clinical Toxicology
Diane S Aschenbrenner
No abstract text is available yet for this article.
March 2019: American Journal of Nursing
Jan Kolcava, Monika Hulova, Yvonne Benesova, Josef Bednarik, Pavel Stourac
BACKGROUND: Natalizumab-related progressive multifocal leukoencephalopathy (PML) is associated with the presence of anti-John Cunningham virus (JCV) antibodies. The aim of this investigation was to evaluate the long-term stability of anti-JCV antibody serum levels and their relation to various demographic, clinical and radiological characteristics in patients suffering from multiple sclerosis (MS). METHODS: Seventy-eight relapsing-remitting MS patients treated with natalizumab and evaluated for the presence of serum anti-JCV antibodies over a time period of 1-6 years (3-11 samples) were included in the study...
February 14, 2019: Multiple Sclerosis and related Disorders
Adam Cuker, Ann D Bass, Congor Nadj, Mark A Agius, Brian Steingo, Krzysztof W Selmaj, Timothy Thoits, Alexandre Guerreiro, Bart Van Wijmeersch, Tjalf Ziemssen, Sven G Meuth, Christopher C LaGanke, Karthinathan Thangavelu, Claudio E Rodriguez, Darren P Baker, David H Margolin, Ann Jannsens
BACKGROUND: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. OBJECTIVE: To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss postmarketing experience outside clinical trials. METHODS: CAMMS223 and Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) I and II investigated two annual courses of alemtuzumab 12 mg (or 24 mg in CAMMS223/CARE-MS II) versus subcutaneous interferon beta-1a three times per week...
February 20, 2019: Multiple Sclerosis: Clinical and Laboratory Research
Bisera Stepanovska, Andrea Huwiler
The past two decades of intense research have revealed a key role of the sphingolipid molecule sphingosine 1-phosphate (S1P) in regulating multiple physiological and pathophysiological processes including cell proliferation and survival, cell migration, inflammatory mediator synthesis and tissue remodeling. S1P mainly acts through five high-affinity G protein-coupled S1P receptors, which are ubiquitously expressed and mediate a complex network of signaling in a cell type dependent manner. S1P receptors have become an attractive pharmacological target to interfere with S1P-mediated cellular responses, which contribute to various autoimmune and inflammatory diseases...
February 15, 2019: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
Gloria Dalla Costa, Vittorio Martinelli, Lucia Moiola, Francesca Sangalli, Bruno Colombo, Annamaria Finardi, Paola Cinque, Eva-Maria Kolb, Aiden Haghikia, Ralf Gold, Roberto Furlan, Giancarlo Comi
This study analyzed serum neurofilament light chains (NfL) in 2 European cohorts of 312 MS patients to investigate whether NfL are biomarkers of PML during natalizumab treatment. The cohort comprised 25 PML, 136 natalizumab-treated, and 151 untreated MS patients. Patients subsequently developing PML had similar NfL to other natalizumab-treated MS patients. At PML onset, NfL were 10-fold higher than in the pre-PML condition and in natalizumab-treated or untreated MS patients, and NfL continued to increase until onset of immune reconstitution inflammatory syndrome...
February 13, 2019: Annals of Neurology
Kazuya Takahashi
Of the 19 cases of fingolimod-associated progressive multifocal leukoencephalopathy (PML) reported worldwide by the end of 2017, 4 cases were from Japan. This may indicate that fingolimod sensitivity is higher in the Japanese population than in the western population because the fingolimod dosage used for the prevention of multiple sclerosis (MS) is the same in both populations. Therefore, the laboratory data of nine patients with MS receiving fingolimod treatment for more than 2 years were retrospectively collected...
February 13, 2019: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
Jonathan Zurawski, Bonnie I Glanz, Alicia Chua, Hrishikesh Lokhande, Dalia Rotstein, Howard Weiner, David Engler, Tanuja Chitnis, Brian C Healy
BACKGROUND: Although the expanded disability status scale (EDSS) is the most commonly used measure of disability for multiple sclerosis, measurement of disability accumulation is complex due to the unequal steps of the scale. OBJECTIVE: To estimate the time between EDSS scores in a large MS cohort from a single center and determine the impact of functional system scores on EDSS transitions. METHODS: 31,394 clinical visits with EDSS scores from 2054 subjects in the CLIMB longitudinal cohort study were included in our analysis...
February 5, 2019: Multiple Sclerosis and related Disorders
Robert Zivadinov, Kiren Kresa-Reahl, Bianca Weinstock-Guttman, Keith Edwards, Chakkarin Burudpakdee, Niels Bergsland, Michael G Dwyer, Bhupendra Khatri, Karthinathan Thangavelu, Jeffrey Chavin, Matt Mandel, Stanley Cohan
AIM: Head-to-head clinical trials of teriflunomide (TFM) versus dimethyl fumarate (DMF) have not been conducted. OBJECTIVES: To compare the real-world effectiveness of TFM versus DMF. METHODS: Anonymized data were collected from patients with relapsing MS initiating treatment with teriflunomide (N = 50) or DMF (N = 50). RESULTS: On follow-up magnetic resonance imaging (MRI) compared with baseline, with TFM versus DMF treatment, the proportion of patients with new/enlarging T2 or gadolinium-enhancing lesions was 30...
February 13, 2019: Journal of Comparative Effectiveness Research
Nathaniel Edward Bennett Saidu, Niloufar Kavian, Karen Leroy, Claus Jacob, Carole Nicco, Frédéric Batteux, Jérôme Alexandre
Dimethyl fumarate (DMF) is a fumaric acid ester registered for the treatment of relapsing-remitting multiple sclerosis (RRMS). It induces protein succination leading to inactivation of cysteine-rich proteins. It was first shown to possess cytoprotective and antioxidant effects in noncancer models, which appeared related to the induction of the nuclear factor erythroid 2 (NF-E2)-related factor 2 (NRF2) pathway. DMF also displays antitumor activity in several cellular and mice models. Recently, we showed that the anticancer mechanism of DMF is dose-dependent and is paradoxically related to the decrease in the nuclear translocation of NRF2...
February 12, 2019: Medicinal Research Reviews
Jens Kuhle, Harald Kropshofer, Dieter A Haering, Uma Kundu, Rolf Meinert, Christian Barro, Frank Dahlke, Davorka Tomic, David Leppert, Ludwig Kappos
OBJECTIVE: To assess the value of blood neurofilament light chain (NfL) as a biomarker of recent, ongoing, and future disease activity and tissue damage and its utility to monitor treatment response in relapsing-remitting multiple sclerosis. METHODS: We measured NfL in blood samples from 589 patients with relapsing-remitting multiple sclerosis (from phase 3 studies of fingolimod vs placebo, FREEDOMS and interferon [IFN]-β-1a, TRANSFORMS) and 35 healthy controls and compared NfL levels with clinical and MRI-related outcomes...
February 8, 2019: Neurology
Malin Boremalm, Alexander Juto, Markus Axelsson, Lenka Novakova, Thomas Frisell, Anders Svenningsson, Jan Lycke, Fredrik Piehl, Jonatan Salzer
BACKGROUND AND PURPOSE: Breakthrough disease on first line injectables in relapsing-remitting multiple sclerosis (RRMS) is a common clinical situation where so far comparative studies between different escalation therapies are lacking. The aim of this study was to compare the efficacy, safety and medication persistence of natalizumab, rituximab and fingolimod as escalation therapy in RRMS METHODS: Patients switching from interferon or glatiramer acetate (INF/GA) to natalizumab, rituximab or fingolimod due to breakthrough disease were identified through the Swedish MS registry at four large MS centers in this retrospective observational study...
February 14, 2019: European Journal of Neurology: the Official Journal of the European Federation of Neurological Societies
Simona Raimo, Daniele Spitaleri, Luigi Trojano, Gabriella Santangelo
BACKGROUND: Behavioral symptoms, such as apathy and depression, are common in multiple sclerosis (MS) but their relationship with cognitive and clinical characteristics often remains underinvestigated and not monitored over time. OBJECTIVE: The aim of this study was to assess the evolution of cognitive profile of patients affected by MS in relation to apathy and depression using a 2-year follow-up study. METHODS: Two years after the first assessment, 100 of 125 MS patients were re-evaluated on a comprehensive neuropsychological battery, and on specific scales for assessment of apathy (Apathy Evaluation Scale-Self-reported) and depression (Hamilton Depression Rating Scale)...
February 7, 2019: Multiple Sclerosis: Clinical and Laboratory Research
Edward Fox, Maria Cecilia Vieira, Kristen Johnson, Miranda Peeples, Arielle G Bensimon, James Signorovitch, Vivian Herrera
OBJECTIVE: To assess real-world durability of reduction in relapse rates among patients with multiple sclerosis (MS) receiving fingolimod therapy over a longer-term period of follow-up. METHODS: Patients with MS who initiated fingolimod were identified from a US claims database (January 1, 2009 to September 30, 2016) and followed for 3 years post-initiation. Annualized relapse rates (ARRs) were calculated during the 1-year pre-initiation period, and during each year over the 3-year follow-up period...
January 22, 2019: Journal of the Neurological Sciences
Joy B Parrish, Emily Fields
Pediatric-onset multiple sclerosis (POMS) is relatively rare, but as technology and neuroimaging advance, an increasing number of cases are identified, and our understanding of how multiple sclerosis (MS) impacts the developing brain improves. There are consistent findings in the literature highlighting the impact of MS and other demyelinating diseases on cognitive functioning and cognitive development. We also have a better understanding of how POMS impacts psychosocial functioning and functional outcomes in daily living...
February 4, 2019: Children
Jonas Graf, Orhan Aktas, Konrad Rejdak, Hans-Peter Hartung
The use of monoclonal antibodies in multiple sclerosis (MS) patients is in a transitional period. Studies regarding well-established, effective antibodies such as natalizumab and alemtuzumab focus more and more on long-term efficacy and safety, risk management, and treating complications. Primary progressive MS, a disease that was long considered to be unmodifiable, is currently in focus following ocrelizumab being approved as the first drug with a proven beneficial effect on the disease course. Conversely, post-marketing safety mechanisms have also proven to function as daclizumab has been suspended after a series of relevant serious adverse events...
January 2, 2019: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Maria R Ciardi, Marco Iannetta, Maria A Zingaropoli, Romina Salpini, Marianna Aragri, Rosanna Annecca, Simona Pontecorvo, Marta Altieri, Gianluca Russo, Valentina Svicher, Claudio M Mastroianni, Vincenzo Vullo
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients...
January 2019: Open Forum Infectious Diseases
James D Bowen, Chris M Kozma, Megan M Grosso, Amy L Phillips
Background: Administrative-claims data enable comparative effectiveness assessment using large numbers of patients treated in real-world settings. Objective: To evaluate real-world relapses, healthcare costs and resource use in patients with MS newly initiating subcutaneous interferon beta-1a (sc IFNβ-1a) v. oral disease-modifying drugs (DMDs: dimethyl fumarate, fingolimod, teriflunomide). Methods: Patients from an administrative claims database (1 Jan 2012-31 Dec 2015) were selected if they: were 18-63 years old; had an MS diagnosis; had newly initiated sc IFNβ-1a, dimethyl fumarate, fingolimod, or teriflunomide (first claim = index); had no evidence of DMD 12-months pre-index; and had 12-month eligibility pre- and post-index...
October 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
2019-02-02 19:05:49
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"